27-Nov-2025 4:55 AM CST - Yahoo Finance Edwards Lifesciences' (NYSE:EW) investors will be pleased with their 20% return over the last year But investors can boost returns by picking market-beating companies to own shares in. For example, the Edwards Lifesciences Corporation (NYSE:EW) share price is up 20% in the last 1 year, clearly besting the market return of around 12% (not including dividends).
25-Nov-2025 3:46 PM CST - Benzinga Here's How Much $1000 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth Today Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 8.71% on an annualized basis producing an average annual return of 17.43%. Currently, Edwards Lifesciences has a market capitalization of $50.38 billion.
5-Nov-2025 11:05 AM CST - Yahoo Finance Is the Options Market Predicting a Spike in Edwards Lifesciences Stock? Investors in Edwards Lifesciences Corporation EW need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 21, 2025 $50.00 Put
30-Oct-2025 4:02 PM CST - Reuters Edwards Lifesciences beats quarterly estimates on strength in heart devices Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in extended trading.
30-Oct-2025 3:13 PM CST - Business Wire Edwards Lifesciences Reports Third Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelli
30-Oct-2025 2:37 PM CST - Reuters Edwards Lifesciences CFO Scott Ullem to step down by mid-2026 Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
Latest EW Trades by Congress Members
12-MAY-2025 - Jefferson Shreve, IN (District 6) sold between $50,001 and $250,000.
27-Nov-2025 4:55 AM CST - Yahoo Finance Edwards Lifesciences' (NYSE:EW) investors will be pleased with their 20% return over the last year But investors can boost returns by picking market-beating companies to own shares in. For example, the Edwards Lifesciences Corporation (NYSE:EW) share price is up 20% in the last 1 year, clearly besting the market return of around 12% (not including dividends).
25-Nov-2025 3:46 PM CST - Benzinga Here's How Much $1000 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth Today Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 8.71% on an annualized basis producing an average annual return of 17.43%. Currently, Edwards Lifesciences has a market capitalization of $50.38 billion.
5-Nov-2025 11:05 AM CST - Yahoo Finance Is the Options Market Predicting a Spike in Edwards Lifesciences Stock? Investors in Edwards Lifesciences Corporation EW need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 21, 2025 $50.00 Put
30-Oct-2025 4:02 PM CST - Reuters Edwards Lifesciences beats quarterly estimates on strength in heart devices Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in extended trading.
30-Oct-2025 3:13 PM CST - Business Wire Edwards Lifesciences Reports Third Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelli
30-Oct-2025 2:37 PM CST - Reuters Edwards Lifesciences CFO Scott Ullem to step down by mid-2026 Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
